Denali Therapeutics

Update in progress

DNLI (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Denali Therapeutics is a biopharmaceutical company focused on therapies for neurodegenerative and lysosomal storage diseases. Its pipeline includes Eclitasertib (SAR443122/DNL758), a RIPK1 inhibitor; BIIB122/DNL151, a LRRK2 inhibitor for Parkinson’s; TAK-594/DNL593 for frontotemporal dementia; DNL126 for Sanfilippo A; DNL310 for Hunter syndrome. It also develops Enzyme Transport Vehicle and OTV programs (DNL952, DNL111, DNL622) and Abeta-targeting DNL921. Formerly SPR Pharma; founded 2013 in South San Francisco.

Company score

Sentiment: -0.05; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.07; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.10; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.04; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.01; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive